![Avatar](https://investorshangout.com/images/ProfileImages/391183169_3725_les-claypool-20090107040855097_640w.jpg)
I dont know what to think about that article. It appears to me to just be a filler article with it's brevity and overly simplistc tone. My gut tells me that Jennifer hasn't done much investigation into Kevetrin but knew enough about it to think a mention of it would make her article look well researched. I am probably wrong, but that is my initial reaction.
That said regardless of my gut reaction; the fact that K is getting a more public mention on a site like Forbes is extremely positive. Jennifer gave just enough information that a curious person, like myself, would likely follow up reading that article with a search on K to see what it was all about. For example; maybe some big fish investor is wasting time during his/her lunch break, reads this seemingly fluff article, and as a result finds K sooner rather than later. You never know what potential that could unlock. The more K trickles into the public eye the faster I think the flood gates will open upon announcements of success in the near future.
![](/m/images/thumb-up.png)
![](/m/images/thumb-down.png)